Bristol Myers Squibb (BMY) Q1 FY25 earnings call

Bristol-Myers Squibb delivered a strong first quarter, driven by robust performance in its growth portfolio and effective cost management, leading to an increase in full-year revenue and EPS guidance. Despite setbacks in two pipeline studies, the company remains confident in its strategic priorities, including advancing its R&D pipeline and pursuing business development opportunities to drive long-term sustainable growth. The focus is on disciplined execution and navigating the complex global operating environment.